Certara, Inc. (NASDAQ:CERT) Receives $15.14 Consensus Target Price from Brokerages

Key Points

• Certara, Inc. has received a consensus rating of "Moderate Buy" from analysts, with four hold ratings and five buy ratings among nine brokerages covering the company.
• The average price target for Certara's stock over the next 12 months is $15.14, following various adjustments made by analysts, including Barclays raising their target from $11.00 to $14.00.
• Certara's recent earnings report showed $0.07 EPS, missing estimates, despite revenue increasing by 12.1% year-over-year to $104.57 million.

Shares of Certara, Inc. (NASDAQ:CERT - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nine ratings firms that are presently covering the company, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $15.1429.

A number of research firms have recently commented on CERT. KeyCorp lowered their target price on Certara from $18.00 to $15.00 and set an "overweight" rating on the stock in a research note on Monday, July 14th. Morgan Stanley began coverage on Certara in a research note on Thursday, July 3rd. They issued an "equal weight" rating and a $16.00 price objective on the stock. JMP Securities restated a "market perform" rating on shares of Certara in a research note on Tuesday, May 6th. Barclays upgraded Certara from an "equal weight" rating to an "overweight" rating and boosted their price objective for the company from $11.00 to $14.00 in a research note on Thursday, May 8th. Finally, UBS Group lowered their price objective on Certara from $17.50 to $15.00 and set a "buy" rating on the stock in a research note on Thursday, August 7th.

Institutional Investors Weigh In On Certara

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AdvisorNet Financial Inc bought a new stake in Certara in the 2nd quarter valued at about $25,000. Versant Capital Management Inc lifted its holdings in shares of Certara by 218.8% in the first quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock worth $27,000 after buying an additional 1,866 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Certara in the first quarter worth about $31,000. Wells Fargo & Company MN lifted its holdings in shares of Certara by 48.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after buying an additional 1,047 shares in the last quarter. Finally, AlphaQuest LLC purchased a new stake in shares of Certara in the first quarter worth about $39,000. 73.96% of the stock is currently owned by institutional investors.

Certara Stock Performance

Shares of NASDAQ CERT traded up $0.06 during mid-day trading on Thursday, reaching $10.87. 966,740 shares of the company's stock were exchanged, compared to its average volume of 1,428,359. The firm has a market capitalization of $1.75 billion, a price-to-earnings ratio of 217.44 and a beta of 1.42. Certara has a 52 week low of $8.64 and a 52 week high of $15.69. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.16 and a quick ratio of 2.16. The firm has a 50-day moving average price of $10.81 and a two-hundred day moving average price of $11.53.

Certara (NASDAQ:CERT - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). The business had revenue of $104.57 million for the quarter, compared to the consensus estimate of $104.14 million. Certara had a return on equity of 5.11% and a net margin of 1.97%.The company's revenue for the quarter was up 12.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.07 earnings per share. Analysts predict that Certara will post 0.28 EPS for the current year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.